|6.21|| +0.055 / +0.89%|
Pacific Biosciences of California, Inc. develops, manufactures and markets an integrated platform for genetic analysis. It has developed a technology to study the synthesis and regulation of DNA combining recent advances in nanofabrication, biochemistry, molecular biology, surface chemistry, and optics. The company has developed a technology platform called single molecule, real-time, or SMRT, technology to study the synthesis and regulation of DNA. SMRT technology uses the natural processing power of enzymes, combined with specially designed reagents and detection systems, to record individual biochemical events. Its initial focus is on DNA sequencing market where a third generation sequencing platform using proprietary SMRT technology, the PacBio RS. The PacBio RS a third generation sequencing instrument that provides real-time information at the single molecule level which includes instrument platform that uses its proprietary consumables, including its SMRT Cells and reagent kits, providing a complete solution to the customer. The company was founded by Stephen Turner and Joseph V. Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
|Mike W. Hunkapiller||Executive Chairman, President & CEO|
|Susan K. Barnes||Executive VP, Chief Financial & Accounting Officer|
|Stephen W. Turner||Chief Technology Officer & Vice President|
|Jonas Korlach||Chief Scientific Officer|
|James Michael Phillips||Senior Vice President-Research & Development|